Catalyst Dossier · compiled by CeliA 🧫

PFIZER (PFE)

Pharmaceutical Preparations · market cap $143.7B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Pfizer is a large-cap, vertically integrated pharmaceutical company with $137B market cap, ~75,000 employees, and $62.6B in revenues (2025), carrying $62.8B net debt largely a legacy of pandemic-era M&A. The company trades at ~$24 with a diversified pipeline spanning oncology, immunology, vaccines, and metabolic disease, with several high-importance catalysts clustered in H2 2026.

The catalyst path

2026-08-04Earningsimp 5/10
2026-08-23 (est.)Phase 2 · PF-07220060 + PF-07104091 combination dose escalationimp 7/10
2026-08-30 (est.)Phase 3 · Elotuzumabimp 9/10
2026-09-15 (est.)Phase 2 · MET233 and MET097imp 7/10
2026-09-21 (est.)Phase 2 · PF-07275315imp 7/10
2026-10-08 (est.)Phase 3 · Rimegepantimp 9/10
2026-10-19 (est.)Phase 2 · PF-07264660imp 7/10
2026-11-29 (est.)Phase 3 · Rimegepantimp 9/10

Pipeline

Asset	Phase	Indication
DVS-233 SR (desvenlafaxine sustained release )	Phase 3	Major Depressive Disorder
PF-08653945	Phase 2	Overweight
Insulin Lispro	Phase 3	Diabetes Mellitus
Cyclosporine A	Phase 3	Renal Transplantation
Prednisone	Phase 2	Prostatic Neoplasms
PF-06826647	Phase 2	Psoriasis
13 valent pneumococcal conjugate vaccine with Polysorbate 80	Phase 3	Vaccines, Pneumococcal
Meropenem	Phase 3	Complicated Intra-abdominal Infections
MET097	Phase 3	Obesity
RSVpreF (Group 1)	Phase 3	RSV
Imipenem-cilastatin	Phase 3	Skin Infection
Diclofenac	Phase 3	Spondylitis, Ankylosing
PF-07850327, ARV-471, vepdegestrant	Phase 2	Locally Advanced or Metastatic ER+ HER2- Breast Cancer
CP-690-550	Phase 2	Arthritis, Rheumatoid
SU-011,248	Phase 2	Kidney Neoplasms
Pediacel	Phase 3	Vaccines, Pneumococcal
Pemetrexed/Cisplatin	Phase 3	NSCLC (Non-small Cell Lung Cancer)
Multivalent Pneumococcal Vaccine - Formulation 1	Phase 2	Pneumococcal Disease
0.04 mg/kg CpG 7909	Phase 2	Carcinoma, Breast
PF-04217329 - Lowest Dose	Phase 2	Primary Open-Angle Glaucoma

Price & technical context

3-month

-11.7%

6-month

-4.6%

12-month

-5.1%

52-wk range

$23.29–$28.55

vs 50-day MA

-4.8%

vs 200-day MA

-6.2%

Realized vol

25.0%

Max drawdown

-31.2%

Daily closes through 2026-07-09. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for PFE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.